5-(hydroxymethyl-6-methylpyridin-2-yl)carbamic acid tert-butyl ester | 305329-56-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-(hydroxymethyl-6-methylpyridin-2-yl)carbamic acid tert-butyl ester
• 英文别名: (5-Hydroxymethyl-6-methyl-pyridin-2-yl)-carbamic acid tert-butyl ester；tert-butyl N-[5-(hydroxymethyl)-6-methylpyridin-2-yl]carbamate
• CAS: 305329-56-0
• 化学式: C₁₂H₁₈N₂O₃
• 分子量: 238.287
• InChiKey: KIYXIGMBBMTGEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  71.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(hydroxymethyl-6-methylpyridin-2-yl)carbamic acid tert-butyl ester 在 氢氧化钾 、 四溴化碳 、 sodium hydride 、 三苯基膦 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 43.0h， 生成 5-(6-tert-butoxycarbonylamino-2-methylpyridin-3-ylmethyl)malonic acid monoethyl ester
  参考文献：
  名称：

  Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa)

  摘要：

  A series of 3-mercapto-propionic acid derivatives that function as reversible inhibitors of carboxypeptidase U have been prepared. We present a successful design strategy using cyclic, low basicity guanidine mimetics resulting in potent, selective and bioavailable inhibitors of carboxypeptidase U (TAFla). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.12.039
• 作为产物：
  描述：

  2-氨基-5-溴-6-甲基吡啶 在 bis-triphenylphosphine-palladium(II) chloride 4-二甲氨基吡啶 、 四丁基氟化铵 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 、 叔丁醇 为溶剂， 反应 52.0h， 生成 5-(hydroxymethyl-6-methylpyridin-2-yl)carbamic acid tert-butyl ester
  参考文献：
  名称：

  Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa)

  摘要：

  A series of 3-mercapto-propionic acid derivatives that function as reversible inhibitors of carboxypeptidase U have been prepared. We present a successful design strategy using cyclic, low basicity guanidine mimetics resulting in potent, selective and bioavailable inhibitors of carboxypeptidase U (TAFla). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.12.039

文献信息

• [EN] NEW COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO2000066557A1

  公开（公告）日：2000-11-09

  The present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts or solvates thereof, or solvates of such salts, which compounds inhibit carboxypeptidase U and thus can be used in the prevention and treatment of diseases associated with carboxypeptidase U. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above.

  本发明涉及式(I)的化合物，以及其药学上可接受的盐或溶剂，或这些盐的溶剂，这些化合物抑制羧肽酶U，因此可用于预防和治疗与羧肽酶U相关的疾病。在进一步方面，本发明涉及用于治疗的本发明化合物；制备这些新化合物的过程；包含本发明化合物中至少一种，或其药学上可接受的盐或溶剂的制药组合物，作为活性成分；以及在制造上述医疗用途的药物中使用活性化合物。
• Pyridine mercapto carboxylic acids as carboxypeptidase U inhibitors
  申请人：Astrazeneca AB

  公开号：US07071175B1

  公开（公告）日：2006-07-04

  The present invention relates to compounds of Formula I, and pharmaceutically acceptable salts or solvates thereof, or solvates of such salts, which compounds inhibit carboxypeptidase U and thus can be used in the prevention and treatment of diseases associated with carboxypeptidase U. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds: to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above.

  本发明涉及式I的化合物，以及其药学上可接受的盐或溶剂或这些盐的溶剂，这些化合物抑制羧肽酶U，因此可用于预防和治疗与羧肽酶U相关的疾病。在进一步方面，本发明涉及用于治疗的本发明化合物；制备这种新化合物的过程；包含本发明化合物中至少一种作为活性成分的药物组合物；以及在制造上述医疗用途的药物中使用活性化合物。
• Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P 1 ′ group
  作者：Philippe G Nantermet、James C Barrow、Stacey R Lindsley、MaryBeth Young、Shi-Shan Mao、Steven Carroll、Carolyn Bailey、Michele Bosserman、Dennis Colussi、Daniel R McMasters、Joseph P Vacca、Harold G Selnick

  DOI：10.1016/j.bmcl.2004.02.033

  日期：2004.5

  Structural modifications of the aminopyridine P'(1), group of imidazole acetic acid based TAFla inhibitors led to the discovery of the aminocyclopentyl analog 28, a 1 nM TAFla inhibitor with CLT50 functional activity of 14 nM but without selectivity against CPB. While not as active, aminobutyl derivative 27 provided an improved 6.7-fold selectivity for TAFla versus CPB. (C) 2004 Elsevier Ltd. All rights reserved.
• NEW COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1180098A1

  公开（公告）日：2002-02-20
• US7071175B1
  申请人：——

  公开号：US7071175B1

  公开（公告）日：2006-07-04